FDA Approve Perrigo Generic Version of BenzaClin® Pump Topical Gel

A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. Britain's Prime Minister David Cameron said the government would continue to talk to both Pfizer and AstraZeneca after the British drugmaker on Monday rejected a sweetened offer from the U.S. company. REUTERS/Phil Noble (BRITAIN - Tags: BUSINESS HEALTH)

Perrigo announced that it has received U.S.FDA approval for the generic version of Valeant Pharmaceutical International, Inc.’s BenzaClin® Pump Topical Gel. BenzaClin® Pump Topical Gel (clindamycin phosphate 1% and benzoyl peroxide 5%) is indicated for the topical treatment of acne vulgaris.

Combined generic and branded sales for the twelve months ending February 2016 were $79 million.

Perrigo’s Chief Executive Officer John T. Hendrickson stated, “This Rx product approval and launch provide our customers with convenient, cost effective technologies like the BenzaClin® Pump.


Please enter your comment!
Please enter your name here